Scientists test Ozempic jabs against newcomer Mounjaro head to head in study of 20,000 slimmers...
so who came out on top? READ MORE: Weight loss jabs could help ward off 10-types of cancer, study says By John Ely Deputy Health Editor For Mailonline Published: 16:00, 8 July 2024 | Updated: 16:22, 8 July 2024 e-mail 5 View comments Mounjaro, dubbed the 'King Kong' of new generation of weight loss jabs has beaten its rival Ozempic in a head-to-head battle of blasting bulging waists. American scientists pit the two drugs, which work by mimicking a hormone that makes people feel full, in a study of more than 18,000 adults who took one of the weekly injections for up to a year. At the end of study, patients taking tirzepatide, the ingredient in Mounjaro, were 224 per cent more likely to have lost about a sixth of their body weight than those on Ozempic.
People on Mounjaro, made by US pharma giant Eli Lilly, also lost up to 7 per cent more weight on average than those on semaglutide, the ingredient in Ozempic. Researchers also found there was no increased risk of adverse side effects like diarrhoea between the two medications. American scientists pit Ozempic and Mounjaro head to head in a study of more than 18,000 adults who took one of the weekly injections for up to a year By weight loss goals Mounjaro was the clear winner with 82 per cent of patients losing at least 5 per cent of their total weight compared to 66 per cent in the Ozempic cohort These charts show the different pro.